ライフサイエンスコーパス: extracorporeal membrane oxygenation

1 patients (33%) were successfully weaned-off extracorporeal membrane oxygenation.

2 of platelet recovery following cessation of extracorporeal membrane oxygenation.

3 eal membrane oxygenation) had surgery before extracorporeal membrane oxygenation.

4 ired inotropic support with 28% treated with extracorporeal membrane oxygenation.

5 his relationship in patients on venoarterial extracorporeal membrane oxygenation.

6 embrane oxygenation compared with venovenous extracorporeal membrane oxygenation.

7 l membrane oxygenation and those who died on extracorporeal membrane oxygenation.

8 arin activity assay therapeutic range during extracorporeal membrane oxygenation.

9 ory cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation.

10 g, and risk factors of acute brain injury in extracorporeal membrane oxygenation.

11 y hemodynamics, was associated with death on extracorporeal membrane oxygenation.

12 chieve a given anticoagulation target during extracorporeal membrane oxygenation.

13 coronavirus 2 patients requiring venovenous extracorporeal membrane oxygenation.

14 urvival compared with those not supported by extracorporeal membrane oxygenation.

15 arin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation.

16 ients undergoing venoarterial and venovenous extracorporeal membrane oxygenation.

17 ) compared with 170.4 hours (70-1,008 hr) on extracorporeal membrane oxygenation.

18 l density thresholds for patients undergoing extracorporeal membrane oxygenation.

19 matic vascular axis imaging after venovenous extracorporeal membrane oxygenation.

20 nt safe catheter ablation under venoarterial extracorporeal membrane oxygenation.

21 r thrombosis in adult patients on venovenous extracorporeal membrane oxygenation.

22 re were 280 peripartum patients who received extracorporeal membrane oxygenation.

23 equired invasive ventilation, and 3 required extracorporeal membrane oxygenation.

24 ost severe cases, mechanical ventilation and extracorporeal membrane oxygenation.

25 embrane oxygenation compared with venovenous extracorporeal membrane oxygenation.

26 orporeal membrane oxygenation and venovenous extracorporeal membrane oxygenation.

27 (32%) were without acute brain injury after extracorporeal membrane oxygenation.

28 cardiogenic shock assisted with venoarterial extracorporeal membrane oxygenation.

29 syndrome patients supported with venovenous extracorporeal membrane oxygenation.

30 erlying pathophysiology that are specific to extracorporeal membrane oxygenation.

31 patients with septic shock may benefit from extracorporeal membrane oxygenation.

32 o venoarterial and 10 patients to venovenous extracorporeal membrane oxygenation.

33 opulmonary resuscitation before venoarterial extracorporeal membrane oxygenation.

34 cardiac dysfunction requiring veno-arterial extracorporeal membrane oxygenation.

35 activity assay for heparin monitoring during extracorporeal membrane oxygenation.

36 te respiratory distress syndrome who require extracorporeal membrane oxygenation.

37 nd were related to physical disability after extracorporeal membrane oxygenation.

38 mbosis and its risk factors after venovenous extracorporeal membrane oxygenation.

39 nagement of the cardiogenic shock patient on extracorporeal membrane oxygenation.

40 cute respiratory distress syndrome requiring extracorporeal membrane oxygenation.

41 coagulation protocol for patients undergoing extracorporeal membrane oxygenation.

42 ulation for patients successfully weaned-off extracorporeal membrane oxygenation.

43 d the serotonin release assay in patients on extracorporeal membrane oxygenation.

44 stics of acute brain injury in patients with extracorporeal membrane oxygenation.

45 n pregnant and peripartum patients receiving extracorporeal membrane oxygenation.

46 syndrome coronavirus 2 requiring venovenous extracorporeal membrane oxygenation.

47 s (1.634; 95% CI, 0.797-3.352; p = 0.18) for extracorporeal membrane oxygenation.

48 requency oscillatory ventilation (HFOV), and extracorporeal membrane oxygenation.

49 iming of acute brain injury in patients with extracorporeal membrane oxygenation.

50 nical circulatory support using venoarterial extracorporeal membrane oxygenation.

51 were significant increases in listings with extracorporeal membrane oxygenation (+1.2%), intra-aorti

52 xygenation (8/156, 5.1%) versus venoarterial-extracorporeal membrane oxygenation (11/142, 7.7%) (p =

53 orporeal membrane oxygenation and venovenous extracorporeal membrane oxygenation (13% vs 10%; p = 0.4

54 verall brain injury compared with venovenous extracorporeal membrane oxygenation (19% vs 10%; p = 0.0

55 enous versus venoarterial versus mixed group extracorporeal membrane oxygenation (23.9 vs 34.4 vs 29.

56 0%), prone positioning (10%), HFOV (9%), and extracorporeal membrane oxygenation (3%).

57 ion was the most frequent complication after extracorporeal membrane oxygenation (37% of patients).

58 r analysis at the initiation of venoarterial extracorporeal membrane oxygenation, 4,918 of these pati

59 receiving invasive mechanical ventilation or extracorporeal membrane oxygenation), 433 (90.4%) comple

60 umonia was the main indication of venovenous extracorporeal membrane oxygenation (46.7%).

61 Survival was lower in venoarterial extracorporeal membrane oxygenation (48%) than venovenou

62 l membrane oxygenation (48%) than venovenous extracorporeal membrane oxygenation (64%) (p < 0.001).

63 d thrombocytopenia in patients on venovenous-extracorporeal membrane oxygenation (8/156, 5.1%) versus

64 Of 25, 22 had venoarterial extracorporeal membrane oxygenation (88%) (nine cardiac

65 ults not receiving mechanical ventilation or extracorporeal membrane oxygenation, a 5-day course of r

66 n variables in patients requiring venovenous extracorporeal membrane oxygenation according to the pat

67 artificial surfaces and shear stress inside extracorporeal membrane oxygenation additionally contrib

68 0.49; p < 0.001), higher PO2 on first day of extracorporeal membrane oxygenation (adjusted odds ratio

69 Patients on extracorporeal membrane oxygenation also followed a simi

70 In-hospital mortality was 30% for venovenous extracorporeal membrane oxygenation and 37.5% for venoar

71 data, including demographics, comorbidities, extracorporeal membrane oxygenation and cannulation char

72 Mean age (+/- SD) of the extracorporeal membrane oxygenation and cardiopulmonary

73 uency of heparin-induced thrombocytopenia in extracorporeal membrane oxygenation and cardiopulmonary

74 support is complex and differs between full extracorporeal membrane oxygenation and extracorporeal C

75 c arrest excluded) who required venoarterial extracorporeal membrane oxygenation and for whom subling

76 is of vascular complications associated with extracorporeal membrane oxygenation and identify prognos

77 tion and intra-aortic balloon pump in 2, and extracorporeal membrane oxygenation and Impella CP in 1.

78 wedge pressure and shunting were worsened by extracorporeal membrane oxygenation and improved by Impe

79 2, extracorporeal membrane oxygenation in 2, extracorporeal membrane oxygenation and intra-aortic bal

80 Commencement of venovenous extracorporeal membrane oxygenation and more organ failu

81 Although extracorporeal membrane oxygenation and other modalities

82 did not differ between patients who died on extracorporeal membrane oxygenation and those successful

83 ers between patients successfully weaned-off extracorporeal membrane oxygenation and those who died o

84 iated coagulopathy differ between venovenous extracorporeal membrane oxygenation and venoarterial ext

85 hemorrhage were similar between venoarterial extracorporeal membrane oxygenation and venovenous extra

86 rall acute brain injury between venoarterial extracorporeal membrane oxygenation and venovenous extra

87 ventilation, sepsis, pulmonary hypertension, extracorporeal membrane oxygenation, and cardiac arrest.

88 ygenation days, plasma on 34% of the days on extracorporeal membrane oxygenation, and cryoprecipitate

89 s (until day 21) of prone position sessions, extracorporeal membrane oxygenation, and inhaled nitric

90 Fibrinogen, weight, indication for extracorporeal membrane oxygenation, and need for hemodi

91 Therapy protocols for treating extracorporeal membrane oxygenation-associated coagulopa

92 The underlying factors of the extracorporeal membrane oxygenation-associated coagulopa

93 ed to characterize the pathomechanism of the extracorporeal membrane oxygenation-associated coagulopa

94 The extracorporeal membrane oxygenation-associated coagulopa

95 y associated with overall mortality, but not extracorporeal membrane oxygenation at the time of heart

96 ant outcomes of patients supported or not by extracorporeal membrane oxygenation at the time of heart

97 5 transplanted patients, 118 (28.4%) were on extracorporeal membrane oxygenation at the time of trans

98 Median time on extracorporeal membrane oxygenation before heart transpl

99 e frequent in venoarterial versus venovenous extracorporeal membrane oxygenation, but described a var

100 py used to prevent circuit thrombosis during extracorporeal membrane oxygenation, but no consensus ex

101 Similar to mechanical ventilation, extracorporeal membrane oxygenation can provide substant

102 cardiogenic shock) and three had venovenous extracorporeal membrane oxygenation cannulation (12%).

103 dical literature identified from MeSH terms: extracorporeal membrane oxygenation, cardiogenic shock,

104 y plays a role in these outcomes and whether extracorporeal membrane oxygenation causes secondary bra

105 From 2015 to 2018, heparin monitoring during extracorporeal membrane oxygenation changed from hourly

106 significantly different in demographics and extracorporeal membrane oxygenation characteristics.

107 In children supported by extracorporeal membrane oxygenation, chest tube bleeding

108 more patients (3.1%) presented with isolated extracorporeal membrane oxygenation circuit dysfunction

109 cal, biochemical, hematologic variables, and extracorporeal membrane oxygenation circuit functional v

110 % CI, 1.00-1.02; p = 0.009), higher rates of extracorporeal membrane oxygenation circuit mechanical f

111 article release were increased in venovenous extracorporeal membrane oxygenation compared to venoarte

112 requent in both venovenous- and venoarterial-extracorporeal membrane oxygenation compared with cardio

113 severe thrombocytopenia were more common in extracorporeal membrane oxygenation compared with cardio

114 In our model, the use of venovenous extracorporeal membrane oxygenation compared with lung p

115 l cardiopulmonary resuscitation venoarterial extracorporeal membrane oxygenation compared with venove

116 Brain injury was more common in venoarterial extracorporeal membrane oxygenation compared with venove

117 respiratory distress syndrome on venovenous extracorporeal membrane oxygenation, compared with curre

118 f the intensivist in the care of patients on extracorporeal membrane oxygenation continues to evolve

119 The strategy of venoarterial extracorporeal membrane oxygenation, coronary angiograph

120 In that context, venoarterial extracorporeal membrane oxygenation could rapidly restor

121 tion curriculum; 2) defining criteria for an extracorporeal membrane oxygenation course as a vehicle

122 dian chest tube blood volume over the entire extracorporeal membrane oxygenation course was 123 mL/kg

123 120% (treatment) or not (control) during the extracorporeal membrane oxygenation course.

124 regarding 1) the creation of a standardized extracorporeal membrane oxygenation curriculum; 2) defin

125 howed a 59% reduction in circuit changes per extracorporeal membrane oxygenation day compared with le

126 ted 75% reduction in the circuit changes per extracorporeal membrane oxygenation day.

127 Platelets were transfused on 68% of extracorporeal membrane oxygenation days, plasma on 34%

128 owed by failure to wean ventilation and post-extracorporeal membrane oxygenation decannulation.

129 orted acute brain injury during venoarterial extracorporeal membrane oxygenation decreased from 10% t

130 ation after circulatory death, initiation of extracorporeal membrane oxygenation, denial of valve rep

131 ory distress syndrome patients on venovenous extracorporeal membrane oxygenation despite the delivery

132 Nearly a third of patients on extracorporeal membrane oxygenation develop vascular com

133 ratio, 1.61; 95% CI, 1.16-2.22; p = 0.004), extracorporeal membrane oxygenation duration (adjusted o

134 Extracorporeal membrane oxygenation duration, cannulatio

135 Extracorporeal membrane oxygenation (ECMO) artificially

136 ces (TCS-VAD) have a survival advantage over extracorporeal membrane oxygenation (ECMO) as a bridge t

137 Extracorporeal membrane oxygenation (ECMO) can be used a

138 ty in mechanical ventilation settings during extracorporeal membrane oxygenation (ECMO) in patients w

139 ases in Pa(CO(2)) that occur when initiating extracorporeal membrane oxygenation (ECMO) in patients w

140 Extracorporeal membrane oxygenation (ECMO) is increasing

141 lvular pump (TV-P) but not with venoarterial extracorporeal membrane oxygenation (ECMO) reduced infar

142 mice and suppresses blood coagulation in an extracorporeal membrane oxygenation (ECMO) setting in ra

143 or health organisations recommend the use of extracorporeal membrane oxygenation (ECMO) support for C

144 cept that more patients who had a history of extracorporeal membrane oxygenation (ECMO) underwent PT

145 arding the outcomes of patients supported by extracorporeal membrane oxygenation (ECMO) who undergo d

146 nt characteristics, the use of pretransplant extracorporeal membrane oxygenation (ECMO), and on index

147 irst randomised clinical trial in the USA of extracorporeal membrane oxygenation (ECMO)-facilitated r

148 date have not investigated its use alongside extracorporeal membrane oxygenation (ECMO).

149 herapy (surgical embolectomy or venoarterial extracorporeal membrane oxygenation [ECMO]) is safe and

150 e a road map for standardizing international extracorporeal membrane oxygenation education and practi

151 ficant variability and limitations in global extracorporeal membrane oxygenation education exist.

152 is two-fold: first, to describe the state of extracorporeal membrane oxygenation education worldwide,

153 ional evidence on the efficacy of venovenous extracorporeal membrane oxygenation for acute respirator

154 c injury in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiac arrest a

155 in-hospital mortality in patients receiving extracorporeal membrane oxygenation for cardiogenic shoc

156 ns of the United States reported no cases of extracorporeal membrane oxygenation for poisoning.

157 d 347 (7.2%) were assisted with venoarterial extracorporeal membrane oxygenation for refractory postc

158 ation in adult patients requiring venovenous extracorporeal membrane oxygenation for respiratory fail

159 wing evidence of the benefit of venoarterial extracorporeal membrane oxygenation for septic cardiomyo

160 tically ill patients supported by venovenous extracorporeal membrane oxygenation for severe acute res

161 ively maintained database of all patients on extracorporeal membrane oxygenation from 2012 to 2018 at

162 patients bridged to heart transplantation on extracorporeal membrane oxygenation had similar survival

163 cardiac or respiratory failure supported on extracorporeal membrane oxygenation had survival rates o

164 rporeal membrane oxygenation or venoarterial extracorporeal membrane oxygenation) had surgery before

165 tation in patients supported by venoarterial extracorporeal membrane oxygenation has been associated

166 During extracorporeal membrane oxygenation, hemodilution and co

167 We evaluated the venoarterial extracorporeal membrane oxygenation impact on macrocircu

168 We aimed to determine whether the timing of extracorporeal membrane oxygenation implantation influen

169 parameter changes found before venoarterial extracorporeal membrane oxygenation implantation regress

170 during the first 48 hours after venoarterial extracorporeal membrane oxygenation implantation were ex

171 e, within 10 days following the venoarterial extracorporeal membrane oxygenation implantation, of a s

172 ampled before, and 1, 24, and 48 hours after extracorporeal membrane oxygenation implantation.

173 pump in 14 patients (67%), Impella CP in 2, extracorporeal membrane oxygenation in 2, extracorporeal

174 ho were successfully treated with venovenous extracorporeal membrane oxygenation in a medical ICU bet

175 to better manage the neurologic sequelae of extracorporeal membrane oxygenation in a way that will i

176 the use of either venoarterial or venovenous extracorporeal membrane oxygenation in critically ill pa

177 ld focus on refining criteria for the use of extracorporeal membrane oxygenation in poisoning.

178 s in the setting of fibrosis, not initiating extracorporeal membrane oxygenation in the baseline scen

179 assess in all research evaluating the use of extracorporeal membrane oxygenation, including adverse e

180 n arterial carbon dioxide tension tension at extracorporeal membrane oxygenation initiation and in-ho

181 weak recommendations in five topic areas of extracorporeal membrane oxygenation initiation and manag

182 actors that influenced the decision to limit extracorporeal membrane oxygenation initiation included

183 as level of lactate just before venoarterial extracorporeal membrane oxygenation initiation seems mor

184 f the cardiopulmonary resuscitation event to extracorporeal membrane oxygenation initiation was assoc

185 es of cardiopulmonary resuscitation prior to extracorporeal membrane oxygenation initiation, 1.04 [95

186 before, and 2, 4, 12, 24, and 48 hours after extracorporeal membrane oxygenation initiation, respecti

187 ulmonary resuscitation prior to venoarterial extracorporeal membrane oxygenation initiation, with 18%

188 Thrombocytopenia is already common at extracorporeal membrane oxygenation initiation.

189 ansplant centers listed more candidates with extracorporeal membrane oxygenation, intra-aortic balloo

190 ciated deep vein thrombosis after venovenous extracorporeal membrane oxygenation is a frequent compli

191 or carefully titrated to specific variables, extracorporeal membrane oxygenation is a mechanical supp

192 Venovenous extracorporeal membrane oxygenation is an effective inte

193 However, extracorporeal membrane oxygenation is associated with a

194 A common theme of the recommendations is extracorporeal membrane oxygenation is best performed by

195 Based on current data, venovenous extracorporeal membrane oxygenation is cost-effective fo

196 Venovenous extracorporeal membrane oxygenation is increasingly bein

197 Peripheral venoarterial extracorporeal membrane oxygenation is increasingly used

198 Venovenous extracorporeal membrane oxygenation is indicated in pati

199 Extracorporeal membrane oxygenation is used to stabilize

200 erience developmental delays for years after extracorporeal membrane oxygenation, it is critical to i

201 rence of brain injury in patients undergoing extracorporeal membrane oxygenation, it is unclear which

202 brain injury is common in patients receiving extracorporeal membrane oxygenation, little is known reg

203 1.425-9.473; overall p = 0.025), duration of extracorporeal membrane oxygenation (< 66 hr: odds ratio

204 Pre-extracorporeal membrane oxygenation macrocirculation, ec

205 A specific protocol for extracorporeal membrane oxygenation management encompass

206 genation support and presents an approach to extracorporeal membrane oxygenation management in the ca

207 Early implantation of extracorporeal membrane oxygenation may help prevent acu

208 tor, hemodynamic and biochemical parameters, extracorporeal membrane oxygenation mode, duration, and

209 ostmortem neuropathologic evaluation, 68% of extracorporeal membrane oxygenation nonsurvivors develop

210 Successful weaning off extracorporeal membrane oxygenation occurred in 60.6% of

211 erall p = 0.017), and renal complications on extracorporeal membrane oxygenation (odds ratio, 2.346;

212 c balloon pumping, Impella, TandemHeart, and extracorporeal membrane oxygenation) on pressures and fl

213 implantation regressed within 12 hours after extracorporeal membrane oxygenation onset.

214 Venovenous extracorporeal membrane oxygenation or standard lung pro

215 One patient per group (venovenous extracorporeal membrane oxygenation or venoarterial extr

216 us extracorporeal ventricular assist system, extracorporeal membrane oxygenation, or a combination of

217 sitive-pressure ventilation, chest drainage, extracorporeal membrane oxygenation, or death).

218 ction categories were associated with use of extracorporeal membrane oxygenation (P < 0.005).Conclusi

219 arin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation (p = 0.79).

220 ive areas related to the care of patients on extracorporeal membrane oxygenation: patient selection,

221 patients compared with 95 in 459 venovenous extracorporeal membrane oxygenation patients (odds ratio

222 poreal membrane oxygenation and venoarterial extracorporeal membrane oxygenation patients and are bes

223 plication occurred in three of 10 venovenous extracorporeal membrane oxygenation patients and in four

224 but was normal in 83% compared with 42.3% of extracorporeal membrane oxygenation patients at day 10.

225 vascular complications in 6,124 venoarterial extracorporeal membrane oxygenation patients compared wi

226 Venoarterial extracorporeal membrane oxygenation patients had more is

227 Venoarterial extracorporeal membrane oxygenation patients had more ov

228 Physical disability in extracorporeal membrane oxygenation patients plays a sig

229 Extracorporeal membrane oxygenation patients with acquir

230 ith a 10-fold increase in interleukin-8 over extracorporeal membrane oxygenation patients without bra

231 Of 10,342 venoarterial extracorporeal membrane oxygenation patients, 401 (3.9%)

232 brain injury was more common in venoarterial extracorporeal membrane oxygenation patients, the rates

233 ith mortality in this cohort of venoarterial extracorporeal membrane oxygenation patients.

234 n patients and in four of eight venoarterial extracorporeal membrane oxygenation patients.

235 embrane oxygenation compared to venoarterial extracorporeal membrane oxygenation patients.

236 onsiderable complication rate in veno-venous extracorporeal membrane oxygenation patients.

237 brane oxygenation and 37.5% for venoarterial extracorporeal membrane oxygenation patients.

238 eparin-induced thrombocytopenia was lower in extracorporeal membrane oxygenation patients.

239 After starting extracorporeal membrane oxygenation, patients were switc

240 of thrombocytopenia less than 100 G/L during extracorporeal membrane oxygenation period, lower the ri

241 In multivariable analysis, lower pre-extracorporeal membrane oxygenation pH (adjusted odds ra

242 were transfused on two third of the days on extracorporeal membrane oxygenation, plasma on one third

243 Even before extracorporeal membrane oxygenation, plasmatic coagulati

244 ne oxygenation circuit functional variables, extracorporeal membrane oxygenation postoxygenator PO2 w

245 dated assessment tools in the development of extracorporeal membrane oxygenation practitioner certifi

246 When extracorporeal membrane oxygenation protocols and teams

247 Extracorporeal membrane oxygenation provides short-term

248 ications reporting vascular complications on extracorporeal membrane oxygenation, published from 1972

249 ood samples drawn from pediatric patients on extracorporeal membrane oxygenation receiving anticoagul

250 The mean age of extracorporeal membrane oxygenation recipients was 54.8

251 rejection-free survival and the frequency of extracorporeal membrane oxygenation-related complication

252 tracorporeal membrane oxygenation as well as extracorporeal membrane oxygenation-related factors that

253 tracorporeal membrane oxygenation as well as extracorporeal membrane oxygenation-related factors.

254 ulmonary vasodilators, prone positioning, or extracorporeal membrane oxygenation (relative risk, 0.51

255 distress syndrome supported with venovenous extracorporeal membrane oxygenation remains high, and th

256 ts were followed until death or venoarterial extracorporeal membrane oxygenation removal.

257 luated 6 hours before and after venoarterial extracorporeal membrane oxygenation removal.

258 nnulation), cannula size, time on venovenous extracorporeal membrane oxygenation, renal failure, and

259 We aimed to identify pre-venoarterial extracorporeal membrane oxygenation risk factors of 90-d

260 ge and familiarity of the issues surrounding extracorporeal membrane oxygenation selection, cannulati

261 Before extracorporeal membrane oxygenation start, patients were

262 nt male sex (HR, 1.701; P=0.0002), recipient extracorporeal membrane oxygenation support (HR, 4.854;

263 vides insights into the physiologic basis of extracorporeal membrane oxygenation support and presents

264 spread use and present lack of data to guide extracorporeal membrane oxygenation support demands that

265 cute rejection before discharge and need for extracorporeal membrane oxygenation support post-transpl

266 The median extracorporeal membrane oxygenation support time was 96

267 After a median of 3 days (1-13 d) on extracorporeal membrane oxygenation support, 37 patients

268 circulation determinants during venoarterial extracorporeal membrane oxygenation support, before futu

269 rrhagic stroke in patients with venoarterial extracorporeal membrane oxygenation support.

270 Among venoarterial extracorporeal membrane oxygenation-supported drug-refra

271 Extracorporeal membrane oxygenation survivors experience

272 Extracorporeal membrane oxygenation survivors' physical

273 onings were less likely to survive following extracorporeal membrane oxygenation than those with othe

274 veness ratio is sensitive to the efficacy of extracorporeal membrane oxygenation therapy and costs.

275 rger trial in patients undergoing venovenous extracorporeal membrane oxygenation to compare different

276 ould undergo routine duplex sonography after extracorporeal membrane oxygenation to detect thrombosis

277 The use of extracorporeal membrane oxygenation to support criticall

278 Despite the increasing use of venoarterial extracorporeal membrane oxygenation to treat severe card

279 vs 9%, P = 0.08) but increased rate of early extracorporeal membrane oxygenation use (12% vs 7%, P =

280 found substantial geographical variation in extracorporeal membrane oxygenation use by geospatially

281 Extracorporeal membrane oxygenation use in poisoned pati

282 latory support, despite the highest rates of extracorporeal membrane oxygenation use.

283 p vein thrombosis frequency after venovenous extracorporeal membrane oxygenation using a CT scan and

284 , we switched from monitoring heparin during extracorporeal membrane oxygenation using activated clot

285 Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increas

286 The early use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) may facili

287 This study assessed venoarterial extracorporeal membrane oxygenation (VA-ECMO) support fo

288 MCS (Impella microaxial pump + venoarterial extracorporeal membrane oxygenation [VA-ECMO]) in refrac

289 o groups (1-yr survival = 85.5% and 80.7% in extracorporeal membrane oxygenation vs nonextracorporeal

290 patients post cardiopulmonary bypass and on extracorporeal membrane oxygenation was 56.25% (18/32) a

291 Extracorporeal membrane oxygenation was employed in the

292 Late implantation of venoarterial extracorporeal membrane oxygenation was independently as

293 Mortality was higher when extracorporeal membrane oxygenation was used for metabol

294 Extracorporeal membrane oxygenation was used in the care

295 After extracorporeal membrane oxygenation weaning, duplex sono

296 Patients weaned-off extracorporeal membrane oxygenation were also evaluated

297 tension (> 20 mm Hg) from the initiation of extracorporeal membrane oxygenation were associated with

298 Only 24% of the days on extracorporeal membrane oxygenation were free of any hem

299 patient died, and all patients treated with extracorporeal membrane oxygenation were successfully we

300 Extracorporeal membrane oxygenation worsened pulmonary c